The report provides a detailed analysis essential for establishing a Cenobamate production plant. It encompasses all critical aspects necessary for Cenobamate production, including the cost of Cenobamate production, Cenobamate plant cost, Cenobamate production costs, and the overall Cenobamate production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Cenobamate production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Cenobamate is a novel tetrazole alkyl carbamate derivative used as an antiepileptic medication for the treatment of partial-onset seizures in adults. It is primarily used as an antiepileptic drug for the treatment of focal-onset seizures in adults with epilepsy, which helps to reduce the frequency and severity of seizures. It serves as an adjunctive therapy used in combination with other seizure drugs to enhance control in patients who have not responded well to prior treatments. It finds its main applications in neurology, where it helps reduce seizure frequency, including those that may spread to generalised tonic-clonic seizures. It is also used in specialised epilepsy care for improving outcomes in treatment-resistant cases. Moreover, it is also used in clinical research to study new therapies for epilepsy and understand neuronal signalling.
The market for cenobamate is primarily driven by its application as a modern antiepileptic medication for seizure management, which significantly strengthens its demand in the medical sector. Its application as an antiepileptic drug in the treatment of partial-onset seizures in adult patients who have not benefited from other antiepileptic drugs also boosts its demand in the pharmaceutical industry.
Its usage as an adjunctive therapy in existing treatment regimens to enhance seizure management and improve patient outcomes further contributes to its demand in the medical and healthcare sectors. Its demand as a valuable drug in comprehensive epilepsy treatment plans and related neurological therapy also supports its demand in neurological care. Advancements in drug synthesis and formulation technologies, supplier reliability, quality assurance practices, and efficient logistics play a vital role in shaping global industrial cenobamate procurement. Moreover, factors such as the cost and availability of raw materials, regulatory approvals, and adherence to safety and environmental guidelines also influence its procurement decisions.
Raw Material for Cenobamate Production
According to the Cenobamate production plant project report, the major raw materials for Cenobamate production include α-Bromo ketone, 1H-tetrazole, Chlorosulfonyl Isocyanate, and Biocatalyst containing oxidoreductase enzyme (from Candida magnoliae).
Production Process of Cenobamate
The extensive Cenobamate production cost report consists of the following industrial production process:
- Production via Chemical Synthesis: The production process of cenobamate begins with treating α-bromo ketone with 1H-tetrazole in DMF using potassium carbonate at room temperature, which forms a 1:1 mixture of tetrazole regioisomers. These are separated by crystallisation from chilled heptane to isolate the desired isomer. Then, this main intermediate undergoes enantioselective enzymatic reduction with RB791 cells expressing oxidoreductase from Candida magnoliae, which converts the ketone to a chiral alcohol in high purity. Finally, the chiral alcohol reacts with chlorosulfonyl isocyanate in THF, followed by water quench and crystallisation, to produce cenobamate as the desired product in good yield.
Cenobamate exists as a white to off-white crystalline powder that is odourless. The molecular formula of the compound is C10H10ClN5O2, and its molecular weight is 267.67 g/mol. It is very soluble in aqueous solutions with a water solubility of approximately 1.7 milligrams per millilitre. It exhibits higher solubility in organic solvents such as ethanol, with a solubility of 209.4 milligrams per millilitre. The compound should be stored at room temperature between 20 degree Celsius and 25 degree Celsius. Common adverse effects include drowsiness, dizziness, fatigue, visual disturbances, and headache, while serious but rare reactions include drug reaction with eosinophilia and systemic symptoms, and QT interval shortening. It is recommended to follow a gradual dose titration schedule to minimise adverse effects and to monitor patients carefully for hypersensitivity reactions, particularly during the initial weeks of treatment.